Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 3/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5823977 | 0.92 | MEN1 (0.53) | MEN1KMT2AMAPK1HTR1AATM | |
| SCHEMBL5899207 | 0.91 | HTR1A (0.62) | MEN1KMT2AHTR1AADRA1DADRA1A | |
| SCHEMBL5818308 | 0.85 | MEN1 (0.53) | MEN1KMT2AMAPK1ATMOPRM1 | |
| SCHEMBL5820590 | 0.83 | MEN1 (0.55) | MEN1KMT2AMAPK1HTR1AADRA1D | |
| SCHEMBL5814914 | 0.81 | HTR1A (0.75) | MEN1KMT2AHTR1AADRA1DADRA1A | |
| SCHEMBL5814935 | 0.79 | MAPK1 (0.62) | MEN1KMT2AMAPK1ATMOPRM1 | |
| SCHEMBL5813989 | 0.79 | ALDH1A1 (0.50) | MEN1KMT2AMAPK1ATMOPRM1 | |
| SCHEMBL5820560 | 0.78 | HTR1A (0.84) | HTR1AADRA1DADRA1AADRA1BDRD2 | |
| SCHEMBL5803590 | 0.77 | MEN1 (0.59) | MEN1KMT2AMAPK1ATMOPRM1 | |
| SCHEMBL5820685 | 0.76 | ADRA1D (0.55) | MEN1KMT2AHTR1AADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183902-A1 | Dihydroindolyl methanones as alpha 1a/1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183902-A1 | Dihydroindolyl methanones as alpha 1a/1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms | ADRA1D, ADRA1A, ADRB1 | MEN1 462/4885KMT2A 3813/4885MAPK1 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.